drugset / Trial / NCT04150224

Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169

NCT04150224

Phase 1 Completed 60 enrolled Nearmedic Plus LLC
RandomizedSequentialOpen-labelBasic science

Summary

Open-label prospective non-comparative ascending dose randomized cohort study of single and multiple oral administration of PBTZ169 (capsules 80 mg) in healthy volunteers

Timeline

Start
2018-07-03
Primary completion
2018-11-23
Completion
2019-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject MACOZINONE Small molecule 640 mg Oral
Subject MACOZINONE Small molecule 960 mg Oral
Subject MACOZINONE Small molecule 1280 mg Oral

Indications

No indication recorded.